Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms

Exclusion Criteria

• •1. History or presence of any medical condition or abnormal laboratory test findings at screening that could affect the study conduct/results, or make the participant unlikely to fully complete the study or potentially adversely affect their safety due to taking part.
• •2. History of non-self-limiting gastrointestinal disorders, or currently suffering from disease known to impact gastric emptying, e.g. migraine, Type 1 or Type 2 diabetes mellitus.
• •3. Any contraindication to gamma scintigraphy.
• •4. Any non-removable metal objects such as metal plates, screws in the chest or abdominal area.
• •5. Total radiation dosimetry value which contraindicates participation.
• •6. Use of prescribed medication within 14 days prior to first dose which could interfere with the study procedures or affect gastric emptying and/or gut transit.
• •7. Use of over-the-counter (OTC) medication, including vitamins, pro and prebiotics and natural or herbal remedies, within 48 hours prior to first dose.
• •8. History of alcohol or other substance abuse.
• •9. Current smoker or recently discontinued smoking (less than 3 months).
• •10. History of allergy to any component of the dosage form or any other allergy which contraindicates participation.
• •11. Vegetarian or vegan.
• •12. Participation in this or another clinical study with an investigational drug within the prior 12 weeks, or more than four other clinical studies in the prior 12 month period.
• •13. Participants unwilling to comply with contraception requirements from first dose until 90 days (use of condom/spermicide in addition to use of protocol-specified highly effective contraception by female partners who could become pregnant)